Cargando…

Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that activate the immune system, aiming at enhancing antitumor immunity. Their clinical efficacy is well-documented, but the side effects associated with their use are still under investigation. These drugs cause several immune-related ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melissaropoulos, Konstantinos, Klavdianou, Kalliopi, Filippopoulou, Alexandra, Kalofonou, Fotini, Kalofonos, Haralabos, Daoussis, Dimitrios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247001/ https://www.ncbi.nlm.nih.gov/pubmed/32403289 http://dx.doi.org/10.3390/ijms21093389

Ejemplares similares

Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases
por: Klavdianou, Kalliopi, et al.
Publicado: (2021)

Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study
por: Daoussis, Dimitrios, et al.
Publicado: (2020)

Molecular Mechanisms of New Bone Formation in Axial Spondyloarthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2022)

Dkk1: A key molecule in joint remodelling and fibrosis
por: Klavdianou, Kalliopi, et al.
Publicado: (2017)

Rheumatic complications in cancer patients treated with immune checkpoint inhibitors
por: Lee, Kyung-Ann, et al.
Publicado: (2019)

PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors
por: Dimitrakopoulos, Foteinos-Ioannis, et al.
Publicado: (2020)

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Shen, Pan, et al.
Publicado: (2021)

Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells
por: Melissaropoulos, Konstantinos, et al.
Publicado: (2022)

Identification of a seasonal pattern to brain metastases
por: Sakellakis, Minas, et al.
Publicado: (2016)

Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors
por: Vilariño, Noelia, et al.
Publicado: (2020)

Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept study
por: Ntelis, Konstantinos, et al.
Publicado: (2016)

Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)

Expression Of Intracellular Components of the NF-κB Alternative Pathway (NF-κB2, RelB, NIK and Bcl3) is Associated With Clinical Outcome of NSCLC Patients
por: Dimitrakopoulos, Foteinos-Ioannis D., et al.
Publicado: (2019)

Skin Manifestation Induced by Immune Checkpoint Inhibitors
por: Yamamoto, Toshiyuki
Publicado: (2022)

JAK Inhibitors for the Treatment of Axial Spondyloarthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2023)

Rheumatic Immune-Related Adverse Events—A Consequence of Immune Checkpoint Inhibitor Therapy
por: Bobircă, Anca, et al.
Publicado: (2021)

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
por: Xiao, Yan, et al.
Publicado: (2020)

Small Extracellular Vesicles (sEVs) Biogenesis Molecular Players Are Associated with Clinical Outcome of Colorectal Cancer Patients
por: Kottorou, Anastasia, et al.
Publicado: (2023)

Quiescent Systemic Lupus Erythematosus Manifesting with Thrombotic Thrombocytopenic Purpura and Acute Renal Failure: A Case Report and Short Literature Review
por: Melissaropoulos, Konstantinos, et al.
Publicado: (2021)

Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update
por: Dang, Quang Minh, et al.
Publicado: (2023)

Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment
por: Thomas, Konstantinos, et al.
Publicado: (2020)

Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions
por: Daoussis, Dimitrios, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Immune checkpoint receptors in regulating immune reactivity in rheumatic disease
por: Ceeraz, Sabrina, et al.
Publicado: (2014)

Cutaneous manifestations associated with immune checkpoint inhibitors
por: Watanabe, Tomoya, et al.
Publicado: (2023)

Expression of Immune System-Related Membrane Receptors CD40, RANK, BAFFR and LTβR is Associated with Clinical Outcome of Operated Non-Small-Cell Lung Cancer Patients
por: Dimitrakopoulos, Foteinos-Ioannis D., et al.
Publicado: (2019)

Management of rheumatic complications of immune checkpoint inhibitor therapy – an oncological perspective
por: Steven, Neil M, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018)

Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies
por: Anastasopoulou, Amalia, et al.
Publicado: (2023)

Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management
por: Zarifa, Abdulrazzak, et al.
Publicado: (2021)

DISH vs Spondyloarthritides
por: Angelopoulou, Fotini, et al.
Publicado: (2020)

Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
por: Zeng, Li, et al.
Publicado: (2023)

Main Oral Manifestations in Immune-Mediated and Inflammatory Rheumatic Diseases
por: Gualtierotti, Roberta, et al.
Publicado: (2018)

Genetic Variations of CD40 and LTβR Genes Are Associated With Increased Susceptibility and Clinical Outcome of Non-Small-Cell Carcinoma Patients
por: Dimitrakopoulos, Foteinos-Ioannis D., et al.
Publicado: (2021)

Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature
por: Benfaremo, Devis, et al.
Publicado: (2018)

Rheumatic manifestations in diabetic patients
por: Serban, AL, et al.
Publicado: (2012)

Activation Markers on B and T Cells and Immune Checkpoints in Autoimmune Rheumatic Diseases
por: Gerasimova, Elena V., et al.
Publicado: (2022)

NF-κB2 and RELB offer prognostic information in colorectal cancer and NFKB2 rs7897947 represents a genetic risk factor for disease development
por: Antonacopoulou, Anna, et al.
Publicado: (2020)

Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed
por: Daoussis, Dimitrios, et al.
Publicado: (2021)

How we treat endocrine complications of immune checkpoint inhibitors
por: Paschou, S.A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n0ohfdhn0bqlo3a9u4v0185s35